Webinar Date/Time: Tue, Mar 14, 2023 11:00 AM EDT
Don’t Freeze To Death. Optimize your drug viability during freeze/thaw cycles by taking control over the freeze.
Register Free: https://www.biopharminternational.com/bp_w/freeze
Event Overview:
A prerequisite for controlled fluid management and freezing applications in biopharmaceutical manufacturing processes is an understanding of the characteristics of your drug substance. Consideration of the mechanisms and implications will help improve manufacturing freezing cycles in a range of applications, such as:
Discover how modular and yet universal freezing technologies improve product quality of your drug substances during cold chain logistics.
Key Learning Objectives:
Speakers:
Roland Jenewein
Chief Technology Officer (CTO)
Single Use Support GmbH
Roland Jenewein is Chief Technology Officer (CTO) at Single Use Support. In this role, Mr. Jenewein oversees product line management, innovation, engineering, project management, and after-sales service. By delivering novel process technologies, he contributes to the company’s goal to pioneer fluid management topics with a focus on freeze-thaw and frozen storage as well as logistics for high value drug substances. Born in Tyrol, Austria, Roland Jenewein has more than 20 years’ experience in engineering, serving in a variety of roles at INNIO (formerly GE Power) from sales application engineer to team leader project management until he joined Single Use Support in 2020.
Register Free: https://www.biopharminternational.com/bp_w/freeze
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 2nd 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.